Biocompatible ocular implants

• US 5,824,072 A
• Filed: 08/14/1996
• Issued: 10/20/1998
• Est. Priority Date: 11/15/1993
• Status: Expired due to Term

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Oculex Pharmaceuticals, Inc. (Abbvie Incorporated)
• Inventors: Wong, Vernon G.
• Primary Examiner(s): SHAY, RANDY CITRIN
• Application Number:
  US08/698,238
• Time in Patent Office: 797 Days
• Field of Search: 623/4, 623/5, 604/294, 604/890.1, 604/891.1, 604/892.1, 424/426-429
• US Class Current: 128/898
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Implants comprising active agents are employed for introduction into a suprachoroidal space or an avascular region of an eye for therapeutic purposes. The administration of drugs is controlled and maintained for long periods of time, while ensuring the substantial absence of significant levels outside the site of administration.

Claims

1. A method for treating an eye condition which comprises:

providing an implant comprising a physiologically active therapeutic agent encapsulated in a pharmacologically acceptable biocompatible polymer;

producing by surgical means an avascular region external to the vitreous and proximal to the site of said eye condition; and

introducing said implant into the avascular region produced by said surgical means, thereby permitting diffusion of said therapeutic agent from said implant into the vitreous, and in proximity to said eye condition;

wherein said agent is maintained at an effective dosage for said eye condition at the site of said eye condition for an extended period of time.

2. The method of claim 1, wherein said avascular region comprises a suprachoroidal space, where the sclera is cut to expose the suprachoroid.

3. The method of claim 1, wherein said surgical means comprises laser ablation.

4. The method of claim 1, wherein said surgical means comprises photocoagulation.

5. The method of claim 1, wherein said surgical means comprises cryotherapy.

6. The method of claim 1, wherein said surgical means comprises heat coagulation.

7. The method of claim 1, wherein said surgical means comprises cauterization.

8. A method for treating an eye condition which comprises:

providing an implant comprising a non-biodegradable outer surface and a refillable reservoir, said reservoir comprising a physiologically active therapeutic agent;

producing by surgical means an avascular region external to the vitreous and proximal to the site of said eye condition; and

introducing said implant into the surgically-induced avascular region produced by said surgical means, thereby permitting diffusion of said therapeutic agent form said implant into the vitreous, and in proximity to said eye condition;

wherein said agent is maintained at an effective dosage for said eye condition at the site of said eye condition for an extended period of time.

9. The method of claim 8, wherein said surgically-induced avascular region comprises a suprachoroidal space, where the sclera is cut to expose the suprachoroid.

10. The method of claim 8, wherein said surgical means comprises laser ablation.

11. The method of claim 8, wherein said surgical means comprises photocoagulation.

12. The method of claim 8, wherein said surgical means comprises cryotherapy.

13. The method of claim 8, wherein said surgical means comprises heat coagulation.

14. The method of claim 8, wherein said surgical means comprises cauterization.

15. The method of claim 8, further comprising the additional step of refilling said implant at least once.

16. The method of claim 15, wherein said implant further comprises a self-sealing layer and said refilling step comprises the injection of said therapeutic agent through said self-sealing layer.

17. The method of claim 15, wherein said implant further comprises an inlet and said refilling step comprises the injection of said therapeutic agent through said inlet.